The PEERLESS II Study
PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism
Inari Medical
1,200 participants
Nov 17, 2023
INTERVENTIONAL
Conditions
Summary
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Mechanical Thrombectomy for pulmonary embolism
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot.
Locations(83)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06055920